Fennec Pharmaceuticals Stock News

Fennec Pharmaceuticals Inc (NASDAQ: FENC ) said it expects to receive a Complete Response Letter (CRL) from the FDA regarding its marketing application for Pedmark. Related Link: Fennec Pharma Stock Is Trading Higher As Pedmark Is Under FDA Review For Full story available on Benzinga.com

FDA Pre-Approval Inspection Identified Deficiencies with the Facility of the Drug Product Manufacturer, Which Require Resolution Prior to PEDMARK Approval FDA Pre-Approval Inspection Identified Defici

FDA Pre-Approval Inspection Identified Deficiencies with the Facility of the Drug Product Manufacturer, Which Require Resolution Prior to PEDMARK Approval FDA Pre-Approval Inspection Identified Deficiencies with the Facility of the Drug Product Manufacturer, Which Require Resolution Prior to PEDMARK Approval

Adherex Technologies Inc. (FENC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that ma

Renaissance Technologies LLC acquired a new position in Fennec Pharmaceuticals Inc (NASDAQ:FENC) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 20,284 shares of the companys stock, valued at approximately $148,000. Other institutional investors and hedge funds have also recently bought and sold shares of the company. Virtu Financial LLC bought a new position []

Fennec Pharmaceuticals Inc (NASDAQ: FENC) said it expects to receive a Complete Response Letter (CRL) from the FDA regarding its marketing application for Pedmark. Related Link:   Fennec Pharma St

The stock price of Fennec Pharmaceuticals Inc (NASDAQ: FENC) fell by over 35% pre-market today. This is why it happened.

Zacks Investment Research lowered shares of Fennec Pharmaceuticals (NASDAQ:FENC) from a buy rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports. According to Zacks, Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in [] The post Zacks Investment Research Lowers Fennec Pharmaceuticals (NASDAQ:FENC) to Hold appeared first on ETF Daily News .

Zacks Investment Research cut shares of Fennec Pharmaceuticals (NASDAQ:FENC) from a buy rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports. According to Zacks, Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in []

Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reportin

Zacks Investment Research upgraded shares of Fennec Pharmaceuticals (NASDAQ:FENC) from a hold rating to a buy rating in a research note released on Friday, Zacks.com reports. Zacks Investment Research currently has $10.00 target price on the stock. According to Zacks, Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of []

Fennec Pharmaceuticals Inc (NASDAQ:FENC) – Wedbush lifted their FY2022 earnings per share estimates for shares of Fennec Pharmaceuticals in a report issued on Wednesday, November 10th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of $0.21 for the year, up from their previous forecast of $0.20. Wedbush also issued […]

Fennec has a PDUFA date upcoming on Nov. 27 for its sodium thiosulfate formulation to treat hearing loss in children undergoing platinum-based chemotherapy. The company has been working on bringing Pe

If you are looking for stocks that are well positioned to maintain their recent uptrend, Adherex Technologies Inc. (FENC) could be a great choice. It is one of the several stocks that passed through o